Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2026Blood AdvancesOpen Access

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMark J. LevisMHMehdi HamadaniBLBrent R Logan

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates gilteritinib's efficacy post-HCT in AML, highlighting regional practice effects.

Key Points

  • This research aims to explore how regional differences in practice influence the benefits of gilteritinib after hematopoietic cell transplantation for FLT3-ITD AML patients.
  • Conducted a post-hoc analysis of BMT CTN 1506 (MORPHO) trial data.
  • Compared outcomes based on the timing of Hematopoietic Cell Transplantation (HCT) and prior FLT3 inhibitor use.
  • Assessed measurable residual disease (MRD) levels pre-HCT.
  • Participants transplanted within 120 days from AML diagnosis showed improved survival from post-HCT gilteritinib (P < 0.001).
  • Pre-HCT MRD levels were significantly higher for those transplanted within 120 days and those pre-treated with FLT3 inhibitors (P = 0.008).
  • Geographic differences in treatment practices correlated with varied benefits from gilteritinib post-HCT.

Cite This Study

Levis et al. (2026) studied this question.

synapsesocial.com/papers/6a6d98b4e258b358b3c6c845https://doi.org/10.1182/bloodadvances.2026020327
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib2025
  2. 2Gilteritinib maintenance therapy after allogeneic hematopoietic stem cell transplantation in FLT3-mutated AML: A systematic review and meta-analysis2025
  3. 3Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations2026
  4. 4Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapse/refractory FLT3-mutated acute myeloid leukemia2026 · 3 citations
  5. 5Post‐stem cell transplant maintenance in FLT3<sup>mut</sup> acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib2024 · 4 citations